Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

5.00p
   
  • Change Today:
    -0.35p
  • 52 Week High: 5.90
  • 52 Week Low: 1.09
  • Currency: UK Pounds
  • Shares Issued: 499.72m
  • Volume: 16,564,280
  • Market Cap: £24.99m
  • RiskGrade: 328
  • Beta: 0.11

Deal with Barclays    Trade now with Barclays Stockbrokers

Immupharma Overview

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE 484.1%  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book n/a  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Immupharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 0.13 (7.25) 3.43p 3.9 n/a n/a n/a 0.0%
31-Dec-21 0.12 (8.94) (3.25)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (4.46) (1.26)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (3.42) (0.81)p n/a n/a n/a n/a 0.0%
31-Dec-24 n/a (2.78) (0.60)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Immupharma Company Announcements

Appointments of CSO and Head of R&D 01-Sep-2025 14:12 RNS
ImmuPharma Files New Patent Application for P140: 01-Sep-2025 13:20 RNS
Holding(s) in Company 20-Aug-2025 13:36 RNS

Immupharma ShareCast News

ImmuPharma can't explain near-400% stock jump 28-Jan-2025 ShareCast
ImmuPharma progresses P140 clinical programme wi... 12-Apr-2023 ShareCast
ImmuPharma upbeat after meeting with US partner ... 11-Nov-2022 ShareCast

Latest Immupharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Immupharma Market Data

Currency UK Pounds
Share Price 5.00p
Change Today -0.35p
% Change -6.54 %
52 Week High 5.90
52 Week Low 1.09
Volume 16,564,280
Shares Issued 499.72m
Market Cap £24.99m
Beta 0.11
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
29.39% below the market average29.39% below the market average29.39% below the market average29.39% below the market average29.39% below the market average
21.95% above the sector average21.95% above the sector average21.95% above the sector average21.95% above the sector average21.95% above the sector average
Price Trend
67.97% below the market average67.97% below the market average67.97% below the market average67.97% below the market average67.97% below the market average
40.91% below the sector average40.91% below the sector average40.91% below the sector average40.91% below the sector average40.91% below the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 04-Sep-2025

Time Volume / Share Price
16:03 202,845 @ 4.93p
16:27 42,086 @ 4.90p
16:27 100,000 @ 5.00p
16:18 31,303 @ 4.99p
16:17 100,000 @ 5.00p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page